Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT05503953
PHASE3
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
View on ClinicalTrials.gov
Summary
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
Official title: A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
318
Start Date
2022-09-13
Completion Date
2025-06-10
Last Updated
2026-09-10
Healthy Volunteers
No
Conditions
Interventions
DRUG
AGSAVI
Uptitation
DRUG
AGLS
Uptitration
Locations (1)
AhnGook
Seoul, South Korea